Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation

Parkinsonism and Related Disorders

Volumn 18, Issue 1, 2012, Pages 110-112

  Kwiatkowski, A ^a   Ryckewaert, G ^a   Jissendi Tchofo, P ^a   Moreau, C ^a   Vuillaume, I ^a   Chinnery, P F ^a   Destee A ^a,d   Defebvre, L ^a,b   Devos, D ^c  

^a UNIV LILLE   (France)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

Deferiprone; Extrapyramidal; MRI; Neurodegeneration, brain iron accumulation (NBIA); Treatment

Indexed keywords

5 HYDROXYTRYPTOPHAN; BACLOFEN; BUSPIRONE; DEFERIPRONE; LEVODOPA;

ADULT; BRAIN REGION; CASE REPORT; CEREBELLAR ATAXIA; CHELATION THERAPY; CLINICAL FEATURE; DAILY LIFE ACTIVITY; DENTATE NUCLEUS; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DYSARTHRIA; DYSMETRIA; DYSTONIA; FEMALE; GLOBUS PALLIDUS; HUMAN; LETTER; LONG TERM CARE; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OROFACIAL DYSTONIA; PARKINSONISM; PRIORITY JOURNAL; RED NUCLEUS; SCORING SYSTEM; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE;

FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PYRIDONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84655167560     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.06.024     Document Type: Letter

References (5)

1. Heli H., Mirtorabi S., Karimian K. Advances in iron chelation: an update. Expert Opin Ther Pat 2011 Mar 30, [Epub ahead of print].
2. Fredenburg A.M., Sethi R.K., Allen D.D., Yokel R.A. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 1996, 108:191-199.
3. Forni G.L., Balocco M., Cremonesi L., Abbruzzese G., Parodi R.C., Marchese R. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008, 23:904-907.
4. Chinnery P.F., Crompton D.E., Birchall D., Jackson M.J., Coulthard A., Lombès A., et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007, 130:110-119.
5. Boddaert N., Le Quan Sang K.H., Rötig A., Leroy-Willig A., Gallet S., Brunelle F., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.